JP2010505818A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010505818A5 JP2010505818A5 JP2009531012A JP2009531012A JP2010505818A5 JP 2010505818 A5 JP2010505818 A5 JP 2010505818A5 JP 2009531012 A JP2009531012 A JP 2009531012A JP 2009531012 A JP2009531012 A JP 2009531012A JP 2010505818 A5 JP2010505818 A5 JP 2010505818A5
- Authority
- JP
- Japan
- Prior art keywords
- caco
- disease
- chitin
- pharmaceutical formulation
- disorders
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920002101 Chitin Polymers 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 5
- 238000000034 method Methods 0.000 claims 4
- 239000000126 substance Substances 0.000 claims 4
- 208000002193 Pain Diseases 0.000 claims 3
- 239000006185 dispersion Substances 0.000 claims 3
- 206010004542 Bezoar Diseases 0.000 claims 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 241000238424 Crustacea Species 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 241000238017 Astacoidea Species 0.000 claims 1
- 208000010392 Bone Fractures Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 208000016192 Demyelinating disease Diseases 0.000 claims 1
- 208000018035 Dental disease Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 208000023178 Musculoskeletal disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000004550 Postoperative Pain Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 208000015322 bone marrow disease Diseases 0.000 claims 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 claims 1
- 229910000019 calcium carbonate Inorganic materials 0.000 claims 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims 1
- 239000000920 calcium hydroxide Substances 0.000 claims 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims 1
- 230000003913 calcium metabolism Effects 0.000 claims 1
- 230000028956 calcium-mediated signaling Effects 0.000 claims 1
- 239000001569 carbon dioxide Substances 0.000 claims 1
- 229910002092 carbon dioxide Inorganic materials 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 208000030212 nutrition disease Diseases 0.000 claims 1
- 239000011368 organic material Substances 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 229910000160 potassium phosphate Inorganic materials 0.000 claims 1
- 235000011009 potassium phosphates Nutrition 0.000 claims 1
- 239000002244 precipitate Substances 0.000 claims 1
- 230000001850 reproductive effect Effects 0.000 claims 1
- 230000000717 retained effect Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 238000009738 saturating Methods 0.000 claims 1
- 239000001488 sodium phosphate Substances 0.000 claims 1
- 229910000162 sodium phosphate Inorganic materials 0.000 claims 1
- 239000006228 supernatant Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL178495A IL178495A (en) | 2006-10-05 | 2006-10-05 | Use of cancerous gastric components or artificial calcium containing carbonate, chitin and polypeptide preparations to treat calcium metabolism-related or calcium-signaling conditions |
| PCT/IL2007/001211 WO2008041236A2 (en) | 2006-10-05 | 2007-10-07 | Composition comprising crustacean gastrolith components, calcium carbonate and its use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010505818A JP2010505818A (ja) | 2010-02-25 |
| JP2010505818A5 true JP2010505818A5 (enExample) | 2010-11-18 |
Family
ID=39153987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009531012A Pending JP2010505818A (ja) | 2006-10-05 | 2007-10-07 | 甲殻類の胃石成分を含む組成物とその使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20100098774A1 (enExample) |
| EP (1) | EP2068891B1 (enExample) |
| JP (1) | JP2010505818A (enExample) |
| CN (1) | CN101563091A (enExample) |
| AU (1) | AU2007303786B2 (enExample) |
| CA (1) | CA2665141C (enExample) |
| CY (1) | CY1114930T1 (enExample) |
| DK (1) | DK2068891T3 (enExample) |
| ES (1) | ES2439741T3 (enExample) |
| IL (1) | IL178495A (enExample) |
| PL (1) | PL2068891T3 (enExample) |
| PT (1) | PT2068891E (enExample) |
| SI (1) | SI2068891T1 (enExample) |
| WO (1) | WO2008041236A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8257750B2 (en) * | 1999-04-30 | 2012-09-04 | Kibow Biotech, Inc. | Calcium carbonate compositions for preventing or treating hyperphosphatemia |
| CN101969962B (zh) | 2007-10-22 | 2014-10-22 | 艾玛菲克有限公司 | 包含磷酸化氨基酸、合成的磷酸化肽和胃石蛋白的稳定的无定形碳酸钙 |
| CA3056570C (en) * | 2011-12-13 | 2022-04-19 | Amir Sagi | Amorphous calcium carbonate for the treatment of calcium malabsorption and metabolic bone disorders |
| RU2637019C2 (ru) | 2012-08-07 | 2017-11-29 | Аморфикал Лтд. | Способ получения стабилизированного аморфного карбоната кальция |
| CN105007925A (zh) * | 2013-02-11 | 2015-10-28 | 艾玛菲克有限公司 | 用于加速骨生长的无定形碳酸钙 |
| CN103417635B (zh) * | 2013-08-15 | 2015-05-20 | 张荣惠 | 接骨药 |
| RU2740453C2 (ru) | 2014-07-31 | 2021-01-14 | Аморфикал Лтд. | Неводные жидкие и полутвердые составы аморфного карбоната кальция |
| US12121538B2 (en) | 2015-06-04 | 2024-10-22 | Amorphical Ltd. | Compositions of amorphous calcium carbonate for inhalation, sublingual or buccal administration |
| IL256065B2 (en) * | 2015-06-04 | 2024-04-01 | Amorphical Ltd | Amorphous calcium carbonate stabilized with polyphosphates or bisphosphonates |
| BR122022001962B1 (pt) * | 2015-12-14 | 2023-05-16 | Société des Produits Nestlé S.A. | Composição nutricional sintética, seu uso, e derivado de ácido graxo |
| US11478011B2 (en) | 2015-12-14 | 2022-10-25 | Societe Des Produits Nestle S.A. | Nutritional compositions and infant formula for promoting de novo myealination |
| EP4233907A3 (en) * | 2015-12-14 | 2024-01-10 | Société des Produits Nestlé S.A. | Nutritional compositions and infant formulas to promote myelination in the brain |
| AU2017210259B2 (en) | 2016-01-18 | 2022-11-03 | Amorphical Ltd. | Stabilized amorphous calcium carbonate as a supplement for cell culture media |
| KR20250114395A (ko) | 2016-01-18 | 2025-07-29 | 아모피컬 리미티드 | 신경, 근육 및 불임 질환 또는 병증의 치료를 위한 안정화된 무정형 탄산칼슘 |
| CN114948992A (zh) * | 2016-10-25 | 2022-08-30 | 艾玛菲克有限公司 | 用于治疗白血病的无定形碳酸钙 |
| CA3144221A1 (en) | 2019-07-23 | 2021-01-28 | Amorphical Ltd | Amorphous calcium carbonate for improving athletic performance |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4237147A (en) | 1974-01-04 | 1980-12-02 | Monsanto Company | Stabilized amorphous calcium carbonate |
| US4199496A (en) * | 1974-09-05 | 1980-04-22 | Johnson Edwin L | Process for the recovery of chemicals from the shells of crustacea |
| US5886012A (en) * | 1989-03-22 | 1999-03-23 | Peter K. T. Pang | Method of treatment for disease associated with excessive PHF using combination therapy involving exogenous calcium and calcium channel blockers |
| US20060165784A1 (en) * | 1997-05-06 | 2006-07-27 | Zhao Jin R | Calcium supplement |
| US20030077604A1 (en) * | 2000-10-27 | 2003-04-24 | Yongming Sun | Compositions and methods relating to breast specific genes and proteins |
| JP2002205947A (ja) * | 2000-12-11 | 2002-07-23 | Chafflose Corporation | 水虫治療薬 |
| JP2005501845A (ja) * | 2001-08-16 | 2005-01-20 | メディカル リサーチ カウンシル | キチン微小粒子およびそれらの医学的用途 |
| JP2004081739A (ja) * | 2002-08-29 | 2004-03-18 | Mitsuru Akashi | ハイドロキシアパタイト−ポリマー複合材料の止血用組成物 |
| AU2003271016A1 (en) * | 2003-09-17 | 2005-04-06 | Bio-Wave Institute Of Suzhou Hi-Tech New District Corporation, Ltd. | Use of n-acetyl-d-aminoglycosamine in preparation of drugs for the treatment of cacer and metastasis |
| WO2005115414A2 (en) * | 2004-05-26 | 2005-12-08 | Ben-Gurion University Of The Negev Research And Development Authority | Orally-administrable compositions comprising stable amorphous calcium carbonate |
| AU2005296271A1 (en) * | 2004-10-15 | 2006-04-27 | University Of Tennessee Research Foundation | Methods for inducing apoptosis in adipocytes |
-
2006
- 2006-10-05 IL IL178495A patent/IL178495A/en active IP Right Grant
-
2007
- 2007-10-07 WO PCT/IL2007/001211 patent/WO2008041236A2/en not_active Ceased
- 2007-10-07 ES ES07827185.5T patent/ES2439741T3/es active Active
- 2007-10-07 PL PL07827185T patent/PL2068891T3/pl unknown
- 2007-10-07 PT PT78271855T patent/PT2068891E/pt unknown
- 2007-10-07 SI SI200731375T patent/SI2068891T1/sl unknown
- 2007-10-07 CA CA2665141A patent/CA2665141C/en active Active
- 2007-10-07 JP JP2009531012A patent/JP2010505818A/ja active Pending
- 2007-10-07 EP EP07827185.5A patent/EP2068891B1/en not_active Not-in-force
- 2007-10-07 US US12/443,987 patent/US20100098774A1/en not_active Abandoned
- 2007-10-07 DK DK07827185.5T patent/DK2068891T3/da active
- 2007-10-07 CN CNA200780045195XA patent/CN101563091A/zh active Pending
- 2007-10-07 AU AU2007303786A patent/AU2007303786B2/en not_active Ceased
-
2012
- 2012-12-27 US US13/728,508 patent/US8728533B2/en active Active
-
2013
- 2013-12-20 CY CY20131101156T patent/CY1114930T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010505818A5 (enExample) | ||
| CA2665141C (en) | Composition comprising crustacean gastrolith components and its use | |
| CN105580987B (zh) | 饲料用有机涂敷多孔质颗粒及其制备方法 | |
| Trivedi et al. | Physical, thermal, and spectroscopic characterization of biofield energy treated murashige and skoog plant cell culture media | |
| CN106219720B (zh) | 改善水质、增强免疫力、有益心脑血管疾病的复合矿物质晶体及其制备方法 | |
| Seesanong et al. | Bio-green synthesis of calcium acetate from oyster shell waste at low cost and reducing the emission of greenhouse gases | |
| ATE520627T1 (de) | Calcium- und/oder magnesiumhydroxid mit höherer aktivität und seine zubereitung | |
| KR20180077662A (ko) | 다공성 미네랄 제조방법 및 이를 이용한 수용화된 다공성 미네랄 조성물 제조방법 | |
| Zhang et al. | Fabrication of flower-like hydroxyapatite agglomerates with the assistant of bamboo membrane | |
| KR102036125B1 (ko) | 저분자 저밀도 이온화 미네랄 복합체 및 이의 제조방법 | |
| CN102754741A (zh) | 一种补充海参矿物质的饲料及其制备和使用方法 | |
| JP2699946B2 (ja) | 麦飯石飼料及びその製法 | |
| Xiao et al. | Effect of poly (sodium 4-styrene-sulfonate) on the crystal growth of hydroxyapatite prepared by hydrothermal method | |
| KR20180028146A (ko) | 유해성분이 제거된 안정한 법제유황의 제조방법 | |
| Li et al. | Crystallization of dicalcium phosphate dihydrate with presence of glutamic acid and arginine at 37 C | |
| TWI882135B (zh) | 由發酵液製備胺基酸顆粒之方法 | |
| KR20020016729A (ko) | 유황과 광물질을 소재로한 오리 사료의 제조방법 및 그조성물 | |
| CN108968075A (zh) | 一种提高骨骼健康的组合物及其应用 | |
| Xue | The Role of Mg 2+ and BSA Langmuir Monolayers in Controlling Polymorph and Morphology of CaCO 3 Crystal | |
| CN108658039A (zh) | 一种水制氢材料及其制备方法和应用 | |
| Pazourková et al. | Preparation of calcium deficient hydroxyapatite on vermiculite from China and Africa deposits | |
| WO2014015992A1 (de) | Heilerde-zubereitung | |
| JP3143413B2 (ja) | 麦飯石粉末の製法及び外傷皮膚炎改善剤、入浴剤、消臭剤 | |
| KR20070032537A (ko) | 고농도 미네랄 소금 제조방법 | |
| Xue et al. | The Role of Mg2 and BSA Langmuir Monolayers in Controlling Polymorph and Morphology of CaCO3 Crystal |